To limit these toxicities, in situ delivery of soluble IL-2 has already been tested in a preclinical setting and resulted in the increased infiltration of CD8+ T cells and reduced tumor growth in tumor bearing mice (121, 122). The gene discussed is IL2; the disease is neoplasm.